PCSK9 and familial hyperaldosteronism: In a nationwide multicentre Spanish registry with 3361 adult patients with FH, females had a 49% lower chance of being prescribed a PCSK9 inhibitor than males.27 However, prior studies on FH report no sex differences in adherence to LLT.93,94